Stock hits upper circuit as market cheers global validation of innovative cancer therapy
By S JHA
MUMBAI, July 11, 2025 — Shares of Glenmark Pharmaceuticals skyrocketed nearly 18% on Friday, hitting the upper circuit and closing at ₹2,175, after the company announced a transformational global licensing deal with US biopharma giant AbbVie through its Swiss subsidiary, IGI Therapeutics SA.
According to stock market analytics platform StockEdge, this sharp rally isn’t just a technical spike—it reflects a fundamental re-rating driven by the high-value ISB 2001 deal, which marks Glenmark’s strategic pivot into cutting-edge oncology and autoimmune therapy development.
📈 The Deal: Global Validation with Multibillion-Dollar Potential
Glenmark’s subsidiary IGI Therapeutics SA signed an exclusive global licensing agreement with AbbVie for ISB 2001, a novel bispecific antibody therapy with applications in cancer and autoimmune disorders.
Deal Terms:
- 💰 $700 million upfront payment
- 💸 Up to $1.225 billion in milestone-based payouts
- 💵 Tiered double-digit royalties on global net sales
The deal positions Glenmark as a serious player in the global biologics market and provides immediate liquidity and long-term monetization opportunity.
“This is a massive value unlocking moment for Glenmark shareholders,” StockEdge noted. It further stated that “it’s not just a spike—it could be a structural rerating.”
📊 Market Reaction: Strong Technical & Momentum Indicators
Glenmark’s surge was backed by powerful technical signals:
- ✅ RSI at 78.87, indicating strong bullish momentum
- ✅ White Marubozu candle on the daily chart—a classic bullish breakout pattern
- ✅ Breakout above Upper Bollinger Band, suggesting high volatility upside
- ✅ High delivery volumes, confirming institutional and long-term buying
- ✅ Momentum scores: 1M – 70, 3M – 70, 6M – 92
- ✅ Trading well above its 200-day EMA
“Technical + fundamental alignment = conviction trade,” said StockEdge.
🔬 The Biotech Pivot: Glenmark’s Reinvention
Glenmark has been gradually repositioning itself from a traditional generics-focused pharma player to a biotech-led innovator, and the ISB 2001 deal may signal a turning point.
Market experts said that “ISB 2001 is not just a molecule, it’s Glenmark’s entry ticket into the big league of immuno-oncology. With a partner like AbbVie, the market is now forced to revisit its valuation framework for Glenmark.”
The company’s focus on biologics and next-gen therapeutics comes amid global shifts in pharma R&D where personalized medicine and antibody-based therapies are drawing investor and regulatory attention alike.
⚠️ Risk Radar: Overbought Signals in Short Term
Despite the euphoria, analysts caution against short-term overheating, as StockEdge said in its note shared in its Telegram channel:
- The RSI is approaching extreme overbought territory.
- A brief consolidation or retracement cannot be ruled out.
- Investors are advised to monitor volume consistency and delivery percentage for signs of sustainability.
Yet, for long-term investors, the biotech narrative is compelling.
🧬 What’s Next for Glenmark?
With over $700 million in upfront cash, Glenmark now has firepower to reinvest in R&D and potential bolt-on acquisitions. Analysts speculate the company may now:
- Accelerate other biologic pipelines in immunotherapy.
- Attract further strategic interest from global pharma majors.
- Strengthen its presence in high-margin specialty pharma segments.
🔍 Bottom Line
The AbbVie deal marks a paradigm shift for Glenmark. No longer just a mid-tier Indian generics player, the company has stepped onto the global biotech stage with a blockbuster licensing deal, strong market validation, and financial muscle to back future innovation.
As one fund manager put it, “This could be India’s Genmab moment—the beginning of a biotech rerating story.”
Disclosure: This report is for informational purposes only and does not constitute investment advice.
Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn
